Weiss Ratings Reiterates “Sell (E+)” Rating for 23andMe (NASDAQ:ME)

Weiss Ratings reissued their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a research report released on Saturday,Weiss Ratings reports.

23andMe Stock Down 7.7 %

NASDAQ ME opened at $2.86 on Friday. 23andMe has a twelve month low of $2.65 and a twelve month high of $16.52. The company has a market cap of $74.70 million, a price-to-earnings ratio of -0.19 and a beta of 1.14. The business’s fifty day moving average is $3.46 and its 200 day moving average is $5.18.

23andMe (NASDAQ:ME) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 145.99%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new position in 23andMe during the 4th quarter worth about $26,000. Leavell Investment Management Inc. acquired a new position in shares of 23andMe in the 4th quarter valued at about $32,000. MassMutual Private Wealth & Trust FSB acquired a new position in shares of 23andMe in the 4th quarter valued at about $40,000. AQR Capital Management LLC lifted its stake in shares of 23andMe by 145.8% in the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after purchasing an additional 263,468 shares during the period. Finally, FMR LLC lifted its stake in shares of 23andMe by 24.0% in the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after purchasing an additional 192,099 shares during the period. 36.10% of the stock is owned by institutional investors and hedge funds.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.